On February 11, 2017, Dr. Lapuerta spoke to NorCal CarciNET Community about the challenges of bringing new drugs to market. Some interesting information to think about while you look at the slides. For Lexicon to bring a new drug to market for Carcinoid Syndrome (CS) they have worked nearly 20 years with the last 10 being in a clinical phase. They have at various times employed up to 750 people working on different aspects of the two different drugs they have worked on (one for CS the other for Diabetes). They will have spent nearly $2billion prior to the approval of either of the two drugs (a little less than half on the drug for CS.) 


PDF not showing up.. You can download it here